[Cost-effectiveness of treatment of type 2 diabetes mellitus in México].
| Autor: | Pérez-Lozano DL; Universidad Autónoma de México, Programa de Maestría y Doctorado en Ciencias Médicas y Odontológicas y de la Salud, Unidad de posgrado. Ciudad de México, México., Camarillo-Nava VM; Instituto Mexicano del Seguro Social, Órgano de Operación Administrativa Desconcentrada Norte, Coordinación Auxiliar Médica de Investigación en Salud. Ciudad de México, México., Juárez-Zepeda TE; Universidad del Valle de México, Escuela de Ciencias de la Salud, Dirección de Medicina, Campus Coyoacán. Ciudad de México, México., Andrade-Pineda JE; Instituto Mexicano del Seguro Social, Unidad de Medicina Familiar N°16, OOAD Norte. Ciudad de México, México., Pérez-López D; Instituto Mexicano del Seguro Social, Unidad de Medicina Familiar N°20, OOAD Norte. Ciudad de México, México., Reyes-Pacheco JA; Instituto Mexicano del Seguro Social, Unidad de Medicina Familiar. No. 13. Ciudad de México, México., Lucho-Gutiérrez ZM; Universidad del Valle de México, Escuela de Medicina, Campus Coyoacán. Ciudad de México, México., Carmona-Aparicio L; Secretaria de Salud, Instituto Nacional de Pediatría. Laboratorio de Neurociencias. Ciudad de México, México. |
|---|---|
| Jazyk: | Spanish; Castilian |
| Zdroj: | Revista medica del Instituto Mexicano del Seguro Social [Rev Med Inst Mex Seguro Soc] 2023 Mar 01; Vol. 61 (2), pp. 172-180. Date of Electronic Publication: 2023 Mar 01. |
| Abstrakt: | Background: Type 2 Diabetes Mellitus (DM2) is a public health and socioeconomic problem, generating direct medical costs for its treatment. Objective: To analyze the cost-effectiveness of monotherapy and bitherapy treatments in patients with DM2. Methods: Cost-effectiveness, observational, ambispective, cross-sectional and analytical analysis of files in a first level medical unit. The data in the cost matrix was executed with the Office Excel 2010 program; the most prescribed drug was identified and compared with monotherapy and bitherapy. Results: The annual direct medical costs of the total population were drug cost $118,561.70MN, hospitalization cost $243,756.00MN, consultation cost $327,414.00MN and clinical trial cost $2416.79MN, obtaining an annual total of $692,148.58MN. metformin was the most indicated in monotherapy (88.4%) and as standard therapy it has higher cost-effectiveness compared to glibenclamide. In bitherapy it was metformin/glibenclamide (35.7%) versus the therapeutics of metformin/NPH insulin, metformin/insulin glargine and metformin/dapagliflozin, which had a better cost-effective result, with an incremental cost effectiveness of -$1,128,428.50MN, -$34,365.00 MN, -$119,848.97MN respectively. Conclusions: Metformin presented a better cost-effectiveness ratio in monotherapy, while in bitherapy it was the metformin/NPH insulin association. (© 2023 Revista Médica del Instituto Mexicano del Seguro Social.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|